Safety of PDT-Photofrin® Prior to Lung Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

March 22, 2019

Study Completion Date

March 22, 2019

Conditions
Lung CancerLung Cancer Metastatic
Interventions
DRUG

Porfimer Sodium

Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.

DEVICE

Fiber optic

After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.

Trial Locations (8)

15801

Dubois Medical Center, DuBois

30265

Cancer Treatment Centers of America/Southeastern, Atlanta

33612

Moffitt Cancer Center, Tampa

60007

AMITA Health Alexian Brothers Medical Center, Elk Grove Village

77030

UT MD Anderson Cancer Center, Houston

80045

University of Colorado, Denver

90048

Cedars-Sinai Medical Center, Los Angeles

99204

Providence Health & Services, Spokane

Sponsors
All Listed Sponsors
lead

Concordia Laboratories Inc.

INDUSTRY

NCT03344861 - Safety of PDT-Photofrin® Prior to Lung Surgery | Biotech Hunter | Biotech Hunter